Company Analysis
Sign in

Nurix Therapeutics, Inc. (NRIX)

Nasdaq: NRIX · Pharmaceutical Preparations · Brisbane, CA · filing with the SEC since 2012
Full chart Alerts Compare
Grade5.9
◀ Past 6.2● Present 5.7▶ Future 5.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

15 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Nurix Therapeutics, Inc.’s names, not what it holds today.

Patents granted
15
15 utility, 1976 to Dec 31, 2025
Granted in 2025
3
Against 6 in 2024 and 2 in 2023
Applications published
39
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry8
Pharmaceuticals7
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Nurix Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
39 published
NURIX THERAPEUTICS, INC. its own name
US, as the owner printed on each patent
15 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 2, 202512,485,1443-substituted piperidine compounds for Cbl-b inhibition, and use thereofPharmaceuticalsNURIX THERAPEUTICS, INC.
Aug 5, 202512,377,106Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTKPharmaceuticalsNURIX THERAPEUTICS, INC.
Feb 25, 202512,234,230Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofOrganic fine chemistryNURIX THERAPEUTICS, INC.
Oct 22, 202412,121,540CBL inhibitors and compositions for use in adoptive cell therapyPharmaceuticalsNURIX THERAPEUTICS, INC.
Sep 17, 202412,091,426Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofPharmaceuticalsNURIX THERAPEUTICS, INC.
Jul 30, 202412,049,471Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereofOrganic fine chemistryNURIX THERAPEUTICS, INC.
Jun 25, 202412,016,860Combination therapies with Cbl-b inhibitor compoundsPharmaceuticalsNURIX THERAPEUTICS, INC.
Apr 9, 202411,951,1333-substituted piperidine compounds for Cbl-b inhibition, and use thereofPharmaceuticalsNURIX THERAPEUTICS, INC.
Jan 9, 202411,866,442Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayOrganic fine chemistryNURIX THERAPEUTICS, INC.
Nov 21, 202311,820,781Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayOrganic fine chemistryNURIX THERAPEUTICS, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
May 22, 20252025/0161303COMBINATION THERAPIES WITH CBL-B INHIBITOR COMPOUNDSPharmaceuticalsNurix Therapeutics, Inc.
May 1, 20252025/0136590SUBSTITUTED BENZYL-TRIAZOLE COMPOUNDS FOR CBL-B INHIBITION, AND FURTHER USES THEREOFOrganic fine chemistryNurix Therapeutics, Inc.
May 1, 20252025/0136579SALTS AND FREE BASES OF BIFUNCTIONAL COMPOUND AND POLYMORPH FORMS THEREOFOrganic fine chemistryNurix Therapeutics, Inc.
Feb 13, 20252025/0051344BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOFOrganic fine chemistryNurix Therapeutics, Inc.
Jan 16, 20252025/0017922BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK WITH ENHANCED IMID ACTIVITYPharmaceuticalsNurix Therapeutics, Inc.
Jan 9, 20252025/0009731TOLL-LIKE RECEPTOR THERAPY COMBINATIONS WITH CBL-B INHIBITOR COMPOUNDSPharmaceuticalsNurix Therapeutics, Inc.
Jan 2, 20252025/0002489BIFUNCTIONAL COMPOUNDS FOR DEGRADING ITK VIA UBIQUITIN PROTEOSOME PATHWAYPharmaceuticalsNurix Therapeutics, Inc.
Dec 19, 20242024/0417402SUBSTITUTED PYRROLO[1,2-b]PYRIDAZINES AS BIFUNCTIONAL DEGRADERS OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASESOrganic fine chemistryNurix Therapeutics, Inc.
Dec 12, 20242024/0409555CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOFOrganic fine chemistryNurix Therapeutics, Inc.
Dec 5, 20242024/0400587BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOFPharmaceuticalsNurix Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9 · Organic fine chemistry 7.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton NRIX · research, not advice